<DOC>
	<DOCNO>NCT02427464</DOCNO>
	<brief_summary>The purpose study determine safety efficacy bilateral intramuscular injection VM202 versus placebo treatment painful diabetic neuropathy . A total 477 subject randomize 2:1 ratio one two treatment group : Treatment - VM202 - 318 subject Control - Placebo ( VM202 vehicle ) - 159 subject Randomization stratify current use gabapentin and/or pregabalin .</brief_summary>
	<brief_title>Phase 3 Gene Therapy Painful Diabetic Neuropathy</brief_title>
	<detailed_description>Peripheral neuropathy serious complication diabetes . This form neuropathy carry high risk pain , trophic change autonomic dysfunction . Treatment diabetic peripheral neuropathy ( DPN ) base either pathogenetic mechanism symptomatic relief . A number clinical trial establish symptomatic treatment pathogenetic mechanism , proven treatment strategy strict glycemic control . Clearly , would desirable prevent , impede , reverse disrupt often life-threatening manifestation peripheral neuropathy stimulate growth regeneration peripheral nerve axon . The result previous study suggest VM202 provide magnitude pain relief report pregabalin gabapentin .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>1 . Age ≥ 18 year 75 year ; 2 . Documented history Type I II diabetes current treatment control ( glycosylated hemoglobin A1c ≤ 10.0 % Screening ) currently oral medication / insulin ; 3 . No significant change anticipate diabetes medication regimen ; 4 . No new symptom associate diabetes within last 3 month prior study entry ; 5 . Diagnosis painful diabetic peripheral neuropathy low extremity ; 6 . Lower extremity pain least 6 month ; 7 . Visual analog scale ( VAS ) score ≥ 40 mm Initial Screening ( 0 mm = pain 100 mm severe pain ) ; 8 . Symptoms Brief Pain Neuropathy Screening ( BPNS ) ≤ 5 point difference legs Initial Screening ; 9 . The average daily pain intensity score Daily Pain Sleep Interference Diary complete medication washout ≥ 4 standard deviation ≤ 2 ; 10 . The physical examination component Michigan Neuropathy Screening Instrument Score ( MNSI ) ≥ 3 Initial Screening ; 11 . Subjects gabapentin ( Neurontin ) , pregabalin ( Lyrica ) , duloxetine ( Cymbalta ) painful DPN study entry must stable regimen treatment least 3 month prior study entry ; 12 . If female childbearing potential , negative urine pregnancy test screen use acceptable method birth control study . 1 . Peripheral neuropathy cause condition diabetes ; 2 . Other pain severe neuropathic pain would prevent assessment DPN ; 3 . Progressive degenerative neurological disorder ; 4 . Myopathy ; 5 . Inflammatory disorder blood vessel ( inflammatory angiopathy , Buerger 's disease ) ; 6 . Active infection ; 7 . Chronic inflammatory disease ( e.g. , Crohn 's disease , rheumatoid arthritis ) ; 8 . Positive HIV HTLV Screening ; 9 . Active Hepatitis B C determine Hepatitis B core antibody ( HBcAb ) , antibody Hepatitis B surface antigen ( IgG IgM ; HBsAb ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( AntiHCV ) Screening ; 10 . Subjects know immunosuppression currently receive immunosuppressive drug , chemotherapy radiation therapy ; 11 . Stroke myocardial infarction within last 3 month ; 12 . Specific laboratory value Screening include : Hemoglobin &lt; 8.0 g/dL , WBC &lt; 3,000 cell per microliter , platelet count &lt; 75,000/mm3 , Creatinine &gt; 2.0 mg/dL ; AST and/or ALT &gt; 3 time upper limit normal clinically significant lab abnormality opinion investigator exclusionary ; 13 . Ophthalmologic condition pertinent proliferative retinopathy condition preclude standard ophthalmologic examination ; 14 . Uncontrolled hypertension define sustain systolic blood pressure ( SBP ) &gt; 200 mmHg diastolic BP ( DBP ) &gt; 110 mmHg Screening ; 15 . Subjects recent history ( &lt; 5 year ) new screen find malignant neoplasm except basal cell carcinoma squamous cell carcinoma skin ( excised evidence recurrence one year ) ; subject family history colon cancer first degree relative exclude unless undergone colonoscopy last 12 month negative finding ; 16 . Use follow drug / therapeutic PROHIBITED . Subjects may participate study willing discontinue use drug / therapeutic 7 day prior start 7 Day Daily Pain Sleep Interference Diary . Subjects must refrain take drug undergo therapy duration study : skeletal muscle relaxant , opioids , benzodiazepine ( except stable bedtime dose ) , capsaicin , local anesthetic cream patch , isosorbide dinitrate ( ISDN ) spray , transcutaneous electrical nerve stimulation ( TENS ) , acupuncture 17 . If use gabapentin ( Neurontin ) pregabalin ( Lyrica ) , subject must agree start drug first 6 month study . Subjects medication study entry must maintain stable dose first 6 month study ; 18 . If use duloxetine ( Cymbalta ) , antidepressant ( e.g . amitriptyline venlafaxine ) , antiepileptic ( e.g. , valproic acid , carbamazepine , vigabatrin ) , subject must agree start drug first 6 month study . Subjects medication study entry must maintain stable dose first 6 month study ; 19 . Subjects require &gt; 81 mg daily acetylsalicylic acid ; subject may enrol willing/able switch ≤ 81 mg daily acetylsalicylic acid another medication ; 20 . Subjects require regular COX2 inhibitor drug ( ) nonspecific COX1/COX2 inhibiting drug , high dose steroid ( except inhale steroid ocular steroid ) ; subject may enrol willing/able undergo medication washout prior first dose refrain take drug first 6 month study ; 21 . Major psychiatric disorder within last 6 month would interfere study participation ; 22 . Body mass index ( BMI ) &gt; 45 kg/m2 Screening ; 23 . Any low extremity amputation due diabetic complication ; 24 . Use investigational drug treatment past 6 month , prior participation study VM202 ; 25 . Unable unwilling give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>diabetic</keyword>
	<keyword>neuropathy</keyword>
	<keyword>shoot pain</keyword>
	<keyword>burn pain</keyword>
	<keyword>pin needle pain</keyword>
	<keyword>foot pain</keyword>
	<keyword>ViroMed</keyword>
</DOC>